このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

MIKE-1の医師主導治験 (MIKE-1)

2026年11月10日 更新者:Hiroki Kawashima、Nagoya University

切除不能膵臓癌に対するゲムシタビンおよび Nab-パクリタキセル併用療法による MIKE-1 の第 I/II 相医師主導臨床試験

To evaluate the safety and tolerability of Am80(Generic name: Tamibarotene, Development code: MIKE-1) in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

調査の概要

詳細な説明

Cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment. The most common notion in the CAF research field has been that CAFs promote cancer progression through various mechanisms. Interestingly, however, recent studies have revealed that CAFs are heterogeneous and that CAF subsets that suppress cancer progression (cancer-restraining CAFs [rCAFs]) must exist in addition to well-characterized cancer-promoting CAFs (pCAFs). However, the identity and specific markers of rCAFs have not been reported.

The investigators recently identified Meflin as a specific marker protein of rCAFs in pancreatic and colon cancers. The investigator's studies revealed that rCAFs are similar to a small subset of resident fibroblasts, which is consistent with the famous hypothesis proposed by Micheal Stoker (University of Glasgow) more than 50 years ago, stating that static normal fibroblasts suppress tumor growth. Interestingly, The investigator's lineage tracing experiments showed that Meflin-positive rCAFs differentiate into Meflin-negative pCAFs during cancer progression. These studies revealed that the tumor stroma is comprised of pCAFs and rCAFs, which is analogous to the heterogeneity of tumor-infiltrating immune cells (e.g., protumor regulatory T cells versus antitumor cytotoxic T cells).

The identification of the rCAF marker Meflin enabled the investigators to develop new strategies to convert or reprogram pCAFs to rCAFs. Using a pharmacological approach, The investigators performed a chemical library screen and identified Am80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. Am80 administration improved the sensitivity of pancreatic cancer to chemotherapeutics. These data suggested that the conversion of pCAF to rCAFs may represent a new strategy for pancreatic cancer treatment.

The object of this study is to perform an investigator-initiated clinical study to investigate the effect of AM80 on pancreatic cancer with a combination of conventional tumoricidal agents including gemcitabine and nab-paclitaxel.

研究の種類

介入

入学 (実際)

60

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Aich
      • Nagoya、Aich、日本、466-8560
        • Nagoya University Hospital
    • Tokyo
      • Tokyo、Tokyo、日本
        • The University of Tokyo Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~79年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

  • Inclusion Criteria:

    - Patients who meet all of the following criteria will be eligible for this study. Besides, CTCAE v5.0 will be used to determine the grade of adverse events in this study.

    1. Patients with unresectable pancreatic cancer who are histologically or cytologically diagnosed as adenocarcinoma based on the 7th edition of the Pancreatic Cancer Treatment Protocol and meet the following criteria.

      Patients who have not received any anticancer therapy (radiation therapy, chemotherapy, immunotherapy, surgery, or investigational therapy) for this disease.

    2. Patients who are between 20 and 79 years of age at the time of consent.

    3. Patients with at least one measurable lesion based on RECIST ver 1.1 in the primary pancreatic lesion confirmed by contrast-enhanced CT at the screening.

    4. Patients who are expected to survive for at least 12 weeks after the start of treatment.

    5. Patients who can understand the contents of this study and can give written consent.

    6. Patients with ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1

    7. Patients who meet the following criteria in blood tests within 7 days before enrollment and whose organ functions are preserved (if blood transfusion is used, tests must be performed at intervals of at least 2 weeks afterward)

      • Total bilirubin ≤ upper limit of institutional standard (ULN) x 1.5 (less than or equal to 3.0 mg/dL for patients undergoing ERBD or PTBD)
      • AST (GOT) and ALT (GPT) ≦ ULN × 3 (In the case of abnormal liver function due to malignancy, ≤ ULN × 5)
      • Creatinine ≤ 1.5 mg/dL or
      • Creatinine clearance ≥ 60ml/min If creatinine clearance is not measured, the estimated value should be used.
      • White blood cell count ≥ 3,500/mm3, ≤ 12,000/mm3
      • Neutrophils ≥ 1,500/mm3
      • Platelet count ≥ 100,000/mm3
      • Hemoglobin ≥ 9.0g/dL
      • Prothrombin activity level ≥ 70%
    8. Outpatients who can go to the hospital.

    9. Patients who can swallow or continue to take oral medications.

    10. For women of childbearing potential, patients who can use contraception for at least 30 days before the start of study treatment, during the study period, and for at least 2 years after the end of treatment.

    11. Patients who can undergo biopsy from pancreatic cancer ①within 28 days before the start of the study treatment and ② 8 weeks after the start of the study treatment (Day 57: acceptable range: ±7 days)

  • Exclusion Criteria:

    1. Patients with any of the following complications Patients with poorly controlled heart disease (congestive heart failure, myocardial infarction, or unstable angina within 1 year before enrollment, arrhythmia requiring treatment, etc.) Poorly controlled diabetes or hypertension Active autoimmune disease requiring systemic administration of steroids or immunosuppression therapy Interstitial pneumonia or pulmonary fibrosis (patients with current grade 2 or higher)
    2. Patients who have received other clinical trial drugs or products (excluding existing chemotherapeutic agents and placebo drugs) within 4 weeks before enrolment.
    3. Patients with confirmed brain metastasis (confirmed by head CT or MRI if the patient has symptoms of brain metastasis)
    4. Patients with ascites or pleural effusion requiring drainage.
    5. Patients who fall under any of the following HBs antigen positive HCV antibody positive and HCV-RNA positive HIV antibody positive
    6. Patients with Grade 2 or higher peripheral sensory or motor neuropathy
    7. Patients with multiple cancers (multiple cancers are defined as simultaneous multiple cancers and metachronous multiple cancers with disease-free survival of 5 years or less. lesions equivalent to carcinoma in situ or intramucosal carcinoma that are considered curable by local treatment are not included in multiple cancers)
    8. Patients who have undergone surgery (excluding diagnostic biopsy and review laparoscopy) within 4 weeks before enrollment.
    9. Patients with bleeding disorders or coagulation disorders that preclude the safe biopsy under EUS (e.g., significant intratumoral bleeding, coagulation disorders, history of bleeding disorders, or complications).
    10. Patients with a history of allergy to the trial drug, combination chemotherapy, its additives, or vitamin A products.
    11. Patients requiring anticoagulant medication.
    12. Patients with cerebral infarction, pulmonary infarction, other arterial or venous thrombosis or its sequelae with clinical symptoms.
    13. Patients with gastrointestinal disorders that may affect the absorption of the investigational drug.
    14. Female patients who are pregnant or breastfeeding (unless breastfeeding is discontinued and not resumed).
    15. Male patients whose sex partner is a woman who wishes to become pregnant.
    16. Patients with vitamin A overload.
    17. Patients receiving vitamin A preparations or regularly using vitamin A-containing supplements (patients can be enrolled if the administration is discontinued at the time of obtaining consent).
    18. Other patients deemed inappropriate by the investigator or sub-investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Am80+GEM/nab-PTX (Phase I)

●The dose-limiting toxicity (DLT) assessment period will be set at 4 weeks. After the DLT evaluation period, if no disease progression is observed based on RECIST v1.1, or no unacceptable toxicities are observed in the patient, the investigational drug will be administered orally twice a day after breakfast and dinner for up to 6 courses for each dosage group. However, for the modified dosage level 2 of the Phase I trial, the investigational drug will be administered orally twice a day after breakfast and dinner, starting from the first day (Day 1) of each course, and drug administration will be paused starting from the Day 15 GEM/nab-PTX administration. Furthermore, dose reduction or increase of the investigational drug will not be performed on the same subject.

Level 1: 6 mg (3 capsules). Level 2 & Modified Level 2: 8 mg (4 capsules). Level 0: 4 mg (2 capsules) if DLT seen in >33% of Level 1.

●(Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) are given intravenously.

medicine taken internally

他の名前:
  • タミバロテネ
  • MIKE-1

Administered intravenously at a dose of 1000mg/m2

他の名前:
  • 宝石

Administered intravenously at a dose of 125mg/m2

他の名前:
  • ナブ-PTX
実験的:Am80+GEM/nab-PTX (Phase II)

The investigational drug at the clinically recommended dose determined in the Phase I trial will be administered orally twice a day after breakfast and dinner, starting from the first day (Day 1) of each course, and drug administration will be paused starting from the Day 15 GEM/nab-PTX administration. This will continue for up to 6 courses. Furthermore, dose reduction or increase of the investigational drug will not be performed on the same subject.

medicine taken internally

他の名前:
  • タミバロテネ
  • MIKE-1

Administered intravenously at a dose of 1000mg/m2

他の名前:
  • 宝石

Administered intravenously at a dose of 125mg/m2

他の名前:
  • ナブ-PTX

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Phase I study; DLT (dose-limiting toxicity)
時間枠:The DLT evaluation period is from Day 1, the start date of study drug administration, to Day 28 of Phase I study.

The severity of adverse events will be determined by the investigator based on CTCAE v 5.0.

  • Grade 4 hematologic toxicity that persists for more than 7 days
  • Grade 3 or higher non-hematologic toxicity that persists for more than 7 days despite symptomatic treatment
  • An adverse event that caused the inability to administer both Day 8 and Day 15 of Cycle 1 of GEM or nab-PTX
  • An adverse event that caused the inability to administer Day 8 of the first cycle of GEM or nab-PTX, resulting in a reduced dose of Day 15
The DLT evaluation period is from Day 1, the start date of study drug administration, to Day 28 of Phase I study.
Phase II study; response rate (based on RECIST ver1.1)
時間枠:through phase II study completion,an average of half year.

If each subject has measurable disease, tumor shrinkage efficacy determination (CR, PR, SD, PD, NE) will be performed based on RECIST v1.1.

through phase II study completion,an average of half year.

二次結果の測定

結果測定
メジャーの説明
時間枠
AE(Adverse events)
時間枠:All of the clinical trial period (up to 6 cycles, 28 days per cycle)

Adverse events will be classified and tabulated in MedDRA/J.

All of the clinical trial period (up to 6 cycles, 28 days per cycle)
OS(Overall survival)
時間枠:The time from the date of first dose of MIKE-1 until date of death from any cause. The cut-off date is the end of post-observation for all patients.

The distribution of overall survival will be estimated by the Kaplan-Meier method, the Kaplan-Meier curve will be illustrated, and the median and 95% confidence interval will be calculated.

The time from the date of first dose of MIKE-1 until date of death from any cause. The cut-off date is the end of post-observation for all patients.
PFS(Progression-free survival)
時間枠:The time from date of first dose of MIKE-1 to date of first documentation of disease progression or death, whichever occurs. The cut-off date is the end of post-observation for all patients.

The distribution of progression-free survival will be estimated by the Kaplan-Meier method, the Kaplan-Meier curve will be illustrated, and the median and 95% confidence interval will be calculated.

The time from date of first dose of MIKE-1 to date of first documentation of disease progression or death, whichever occurs. The cut-off date is the end of post-observation for all patients.
Area under the blood concentration time curve (AUC)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Peak Plasma Concentration (Cmax)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Elimination half-life (t1/2)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Clearance (CL)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Mean residence time (MRT)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Volume of distribution (Vds)
時間枠:1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.

Calculate summary statistics

1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
Response rate (Phase I)
時間枠:All of the clinical trial period (up to 6 cycles, 28 days per cycle)

Based on RECIST ver1.1

All of the clinical trial period (up to 6 cycles, 28 days per cycle)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Mitsuhiro Fujishiro、The University of Tokyo Hospital
  • 主任研究者:Hiroki Kawashima、Nagoya University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年8月23日

一次修了 (実際)

2025年10月2日

研究の完了 (実際)

2025年11月1日

試験登録日

最初に提出

2021年8月18日

QC基準を満たした最初の提出物

2021年9月21日

最初の投稿 (実際)

2021年10月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する